Facing blockbuster patent expiry, competition of generics, increased counterfeiting, changing market dynamics, cost pressure, patient safety, shorter time-to-market and increasing regulations, global traditional pharmaceutical companies must achieve market responsiveness and manufacturing efficiency to stay successful.

The development and implementation of MES in the life science industries has been clearly defined by world regulatory institutions such as the FDA. Within the “Pharmaceutical cGMPs for the 21st Century” initiative, FDA regulators expect that the implementation of MES will allow companies to improve manufacturing processes, enforce quality and regulatory compliance and shorten time-to-production and time-to-market.

Siemens MES ensures efficient manufacturing through consolidating and optimizing the number of different manufacturing resources available, including equipment, people, processes and products. It provides real-time production execution as well as availability and analysis of process and quality information to help optimize production activities from order creation to finished goods.